**SUPPLEMENTAL TABLE 1 – Number of trials by therapeutic category - Clinicaltrials.gov**

**Therapeutic category Phase 1 Phase 2 Phase 3 TOTAL**

 **2020 2021 2022 2020 2021 2022 2020 2021 2022 2020 2021 2022**

Anti-inflammatories\* 0 0 1 0 1 0 0 0 0 0 1 1

Antioxidants 0 0 1 2 4 2 0 0 0 2 4 3

Botanicals\*\* 0 0 0 3 0 0 1 0 0 4 0 0

Cell therapy 8 6 9 1 2 2 0 0 0 9 8 11

Dopaminergic symptom relief 12 13 14 6 4 9 16 19 16 34 36 39

Energy and mitochondria 1 2 1 3 2 3 0 0 0 4 4 4

GBA 1 1 1 3 2 1 0 0 0 4 3 2

GLP-1 agonists 1 1 1 4 6 6 1 1 1 6 8 8

Immunotherapy 5 5 3 2 2 1 0 0 0 7 7 4

Kinase inhibitors 3 3 1 1 2 2 0 0 0 4 5 3

Microbiome/GIT 3 3 3 3 2 2 0 0 0 6 5 5

Neurotrophic factors 3 2 2 0 0 1 0 0 0 3 2 3

Non-dopaminergic sympt. relief 6 4 3 26 26 35 9 7 3 41 37 41

Targeting alpha synuclein 2 4 5 2 3 4 1 1 1 5 8 10

Other 6 5 6 10 9 6 0 0 1 16 14 13

TOTAL 51 49 51 66 65 74 28 28 22 145 142 147

\* Introduced as a category in 2021; \*\* Removed as a category in 2021